mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia

We have previously demonstrated that mTOR inhibitors (MTIs) are active in preclinical models of acute lymphoblastic leukemia (ALL). MTIs may increase degradation of cyclin D1, a protein involved in dihydrofolate reductase (DHFR) synthesis. Because resistance to methotrexate may correlate with high D...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Teachey, David T., Sheen, Cecilia, Hall, Junior, Ryan, Theresa, Brown, Valerie I., Fish, Jonathan, Reid, Gregor S. D., Seif, Alix E., Norris, Robin, Chang, Yueh J., Carroll, Martin, Grupp, Stephan A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2008
Gaiak:
Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2518903/
https://ncbi.nlm.nih.gov/pubmed/18544682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-137141
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak